Core Viewpoint - Robbins LLP has initiated a class action lawsuit on behalf of investors who acquired Reckitt Benckiser Group PLC American Depository Shares (ADSs) between January 13, 2021, and July 28, 2024, alleging that the company misled investors regarding the safety of its Enfamil baby formula [1][2]. Allegations - The lawsuit claims that Reckitt failed to inform investors and consumers about the increased risk of necrotizing enterocolitis (NEC) in preterm infants consuming its cow's milk-based formula, Enfamil, and the potential negative impact on sales and legal exposure [2]. - A jury in Illinois awarded $60 million in a case against Mead Johnson, finding negligence related to the same NEC risk, which led to a significant drop in Reckitt's ADS price [3]. - Following a similar case in Missouri, where Abbott Laboratories was found liable for NEC, Reckitt's ADS price also experienced a notable decline [4]. Next Steps - Shareholders interested in participating in the class action must file a motion for lead plaintiff by August 4, 2025, with the option to remain an absent class member if they choose not to take action [5].
RBGLY Shareholders with Large Losses are Encouraged to Seek Counsel - Contact Robbins LLP for Information About Leading the Class Action Against Reckitt Benckiser Group PLC